MedPath

BiLirubin Decrease Under Phototherapy Exposure in the Preterm Newborn in Incubator

Completed
Conditions
Jaundice, Neonatal
Preterm Infant
Phototherapy
Interventions
Other: bilirubin serum level determination
Other: Phototherapy
Registration Number
NCT03942757
Lead Sponsor
Centre Hospitalier Universitaire, Amiens
Brief Summary

Phototherapy is routinely used in neonatal intensive care units for the treatment of jaundice. Guidelines focus mainly on bilirubin serum levels to start the phototherapy. Only few data are available about clinical management of phototherapy devices and subsequently the impact on bilirubin serum decrease. Especially there are no strong recommendations about phototherapy duration, irradiance measurements, incubator temperature and humidity settings. Various factors can influence irradiance and thus the preterm infant bilirubin serum decrease. This study aims at evaluating the impact of an educational program on the use and efficacy of phototherapy in a neonatal intensive care unit.

Detailed Description

Only few data are available about clinical management of phototherapy devices for the treatment of jaundice in the preterm infant.

This study is a prospective, monocentric, observational study. Preterm infant \< 35 weeks of gestation with a jaundice requiring phototherapy according to NICE guidelines can be included for the duration of the phototherapy treatment.

The decrease in bilirubin serum level before and after phototherapy treatment will be measured.

This decrease in bilirubin serum level will be assessed for two consecutive periods before and after an educational program on jaundice management of the preterm infant.

The investigators aim at demonstrating that an educational program could improve phototherapy management and result in a higher decrease in bilirubin serum during treatment of the preterm infant with jaundice.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
200
Inclusion Criteria
  • preterm infant less than 35 weeks gestation
  • preterm infant hospitalized in the neonatal intensive care unit of CHU Amiens-Picardie
  • preterm infant placed in an incubator
  • preterm infant with a jaundice requiring treatment according to NICE guidelines
  • preterm infant with a no hemolytic disease
  • preterm infant with informed written consent from the parents
Exclusion Criteria
  • preterm infant more than 35 weeks of gestation
  • preterm infant with hemolytic disease
  • preterm infant with Jaundice related to a cholestasis
  • Jaundice requiring exchange transfusion

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
observation before educational programbilirubin serum level determination100 preterm infant medical records will be studied in a first part of this observational study
observation before educational programPhototherapy100 preterm infant medical records will be studied in a first part of this observational study
Observation after educational programPhototherapyAn educational program will be implemented in the unit after this first period. 100 preterm infant will be included in a second part of this observational study.
Observation after educational programbilirubin serum level determinationAn educational program will be implemented in the unit after this first period. 100 preterm infant will be included in a second part of this observational study.
Primary Outcome Measures
NameTimeMethod
Change in bilirubin serum level (μmol/L/h)before and 24 hours after start of phototherapy treatment

Change in bilirubin serum level (μmol/L/h) = (end bilirubin (μmol/L) - start bilirubin (μmol/L)) / delay between the 2 measurements (h)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

CHU Amiens

🇫🇷

Amiens, France

© Copyright 2025. All Rights Reserved by MedPath